Fetal origins of adult cardiac disease: a novel approach to prevent fetal growth restriction induced cardiac dysfunction using insulin like growth factor

2017 ◽  
Vol 81 (6) ◽  
pp. 919-925 ◽  
Author(s):  
Tarek Alsaied ◽  
Khaled Omar ◽  
Jeanne F. James ◽  
Robert B. Hinton ◽  
Timothy M. Crombleholme ◽  
...  
Keyword(s):  
Growth Factor ◽  
Fetal Growth ◽  
Cardiac Disease ◽  
Cardiac Dysfunction ◽  
Fetal Growth Restriction ◽  
Growth Restriction ◽  
Insulin Like Growth Factor ◽  
Fetal Origins ◽  
Novel Approach

scholarly journals Fetal growth restriction and the programming of heart growth and cardiac insulin-like growth factor 2 expression in the lamb

2011 ◽  
Vol 589 (19) ◽  
pp. 4709-4722 ◽  
Author(s):  
Kimberley C. W. Wang ◽  
Lei Zhang ◽  
I. Caroline McMillen ◽  
Kimberley J. Botting ◽  
Jaime A. Duffield ◽  
...  
Keyword(s):  
Growth Factor ◽  
Fetal Growth ◽  
Fetal Growth Restriction ◽  
Growth Restriction ◽  
Insulin Like Growth Factor

scholarly journals Effects of intrauterine insulin-like growth factor-1 therapy for fetal growth restriction on adult metabolism and body composition are sex specific

2020 ◽  
Vol 318 (4) ◽  
pp. E568-E578 ◽  
Author(s):  
Ana-Mishel Spiroski ◽  
Mark Hope Oliver ◽  
Anne Louise Jaquiery ◽  
Travis Dane Gunn ◽  
Jane Elizabeth Harding ◽  
...  
Keyword(s):  
Body Composition ◽  
Growth Factor ◽  
Fetal Growth ◽  
Fetal Growth Restriction ◽  
Metabolic Regulation ◽  
Glucose Utilization ◽  
Growth Restriction ◽  
Insulin Like Growth Factor ◽  
Adult Growth ◽  
Acid Ratio

Fetal growth restriction (FGR) is associated with compromised growth and metabolic function throughout life. Intrauterine therapy of FGR with intra-amniotic insulin-like growth factor-1 (IGF1) enhances fetal growth and alters perinatal metabolism and growth in a sex-specific manner, but the adult effects are unknown. We investigated the effects of intra-amniotic IGF1 treatment of FGR on adult growth and body composition, adrenergic sensitivity, and glucose-insulin axis regulation. Placental embolization-induced FGR was treated with four weekly doses of 360 µg intra-amniotic IGF1 (FGRI) or saline (FGRS). Offspring were raised to adulthood (18 mo: FGRI, n = 12 females, 12 males; FGRS, n = 13 females, 10 males) alongside offspring from unembolized and untreated sheep (CON; n = 12 females, 21 males). FGRI females had increased relative lean mass compared with CON but not FGRS ( P < 0.05; 70.6 ± 8.2% vs. 61.4 ± 8.2% vs. 67.6 ± 8.2%), decreased abdominal adipose compared with CON and FGRS ( P < 0.05; 43.7 ± 1.2% vs. 49.3 ± 0.9% vs. 48.5 ± 1.0%), increased glucose utilization compared with FGRS but not CON ( P < 0.05; 9.6 ± 1.0 vs. 6.0 ± 0.9 vs. 7.6 ± 0.9 mg·kg−1·min−1), and increased β-hydroxybutyric acid:nonesterified fatty acid ratio in response to adrenaline compared with CON and FGRS ( P < 0.05; 3.9 ± 1.4 vs. 1.1 ± 1.4 vs. 1.8 ± 1.4). FGRS males were smaller and lighter compared with CON but not FGRI ( P < 0.05; 86.8 ± 6.3 vs. 93.5 ± 6.1 vs. 90.7 ± 6.3 kg), with increased peak glucose concentration (10%) in response to a glucose load but few other differences. These effects of intra-amniotic IGF1 therapy on adult body composition, glucose-insulin axis function, and adrenergic sensitivity could indicate improved metabolic regulation during young adulthood in female FGR sheep.

scholarly journals Mechanisms of impaired nephrogenesis with fetal growth restriction: altered renal transcription and growth factor expression

2008 ◽  
Vol 199 (3) ◽  
pp. 252.e1-252.e7 ◽  
Author(s):  
Ahmed K. Abdel-Hakeem ◽  
Tasmia Q. Henry ◽  
Thomas R. Magee ◽  
Mina Desai ◽  
Michael G. Ross ◽  
...  
Keyword(s):  
Growth Factor ◽  
Fetal Growth ◽  
Fetal Growth Restriction ◽  
Growth Restriction ◽  
Factor Expression ◽  
Growth Factor Expression
Sign in / Sign up

Export Citation Format

Share Document